Citadel Advisors’s Spero Therapeutics SPRO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $301K | Buy |
103,786
+42,470
| +69% | +$123K | ﹤0.01% | 4616 |
|
|
2025
Q1 | $44.1K | Sell |
61,316
-111,556
| -65% | -$80.3K | ﹤0.01% | 5400 |
|
|
2024
Q4 | $178K | Buy |
172,872
+91,447
| +112% | +$94.2K | ﹤0.01% | 4934 |
|
|
2024
Q3 | $109K | Sell |
81,425
-230,609
| -74% | -$309K | ﹤0.01% | 4886 |
|
|
2024
Q2 | $406K | Buy |
+312,034
| New | +$406K | ﹤0.01% | 4003 |
|
|
2024
Q1 | – | Sell |
-32,274
| Closed | -$47.4K | – | 6783 |
|
|
2023
Q4 | $47.4K | Buy |
+32,274
| New | +$47.4K | ﹤0.01% | 5139 |
|
|
2023
Q3 | – | Sell |
-14,956
| Closed | -$21.7K | – | 6460 |
|
|
2023
Q2 | $21.7K | Buy |
+14,956
| New | +$21.7K | ﹤0.01% | 5232 |
|
|
2022
Q3 | – | Sell |
-108,351
| Closed | -$80K | – | 6659 |
|
|
2022
Q2 | $80K | Buy |
108,351
+97,554
| +904% | +$72K | ﹤0.01% | 5369 |
|
|
2022
Q1 | $94K | Buy |
+10,797
| New | +$94K | ﹤0.01% | 5684 |
|
|
2021
Q4 | – | Hold |
0
| – | – | – | 7144 |
|
|
2021
Q3 | – | Sell |
-11,812
| Closed | -$165K | – | 7038 |
|
|
2021
Q2 | $165K | Sell |
11,812
-8,268
| -41% | -$115K | ﹤0.01% | 5704 |
|
|
2021
Q1 | $296K | Sell |
20,080
-12,558
| -38% | -$185K | ﹤0.01% | 5056 |
|
|
2020
Q4 | $633K | Buy |
32,638
+11,328
| +53% | +$220K | ﹤0.01% | 3675 |
|
|
2020
Q3 | $238K | Buy |
+21,310
| New | +$238K | ﹤0.01% | 3997 |
|